EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study

María Clara García-Castillo iD, Álvaro Sierra-Mencía iD, Edoardo Caronna iD, Daniel Toledo-Alfocea iD, Alex Jaimes iD, Sarai Urtiaga, Javier Casas-Limón iD, Albert Muñoz-Vendrell iD, Sonia Santos-Lasaosa iD, Valvanuz García Martín, Guillermo Martín Ávila, Marcos Polanco iD und 26 weitere

Headache: The Journal of Head and Face Pain · 2026-06 · 66 (6) · 1330-1341

DOI: 10.1111/head.70086 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 01.04.2026. Verfasst von María Clara García-Castillo und 37 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Medicina, Universidad Autónoma de Madrid (UAM), Madrid, Spain. Hauptthemen laut MEDLINE: Migraine Disorders, Autoimmune Diseases, Calcitonin Gene-Related Peptide, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III, European Union (FEDER/European Regional Development Fund-"A way to make Europe").

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to evaluate demographic characteristics, treatment effectiveness, and safety outcomes in patients with migraine undergoing anti‐calcitonin gene‐related peptide (CGRP) treatments regarding the presence of autoimmune diseases.

Background

CGRP has an important role in migraine pathophysiology through neuronal modulation in the trigeminovascular nociceptive system and activation of neuro‐inflammatory cascades. We hypothesized that autoimmune diseases may influence treatment response and safety profiles in patients with migraine treated with anti‐CGRP treatments.

Methods

This was a retrospective multicenter, age‐ and sex‐matched cohort study in headache units/headache clinics in Spain and United Kingdom between May 2024 and May 2025 including patients treated with CGRP monoclonal antibodies from prospectively collected cohorts. Patients were assessed for demographics, migraine‐related characteristics, treatment effectiveness (monthly migraine days [MMD] and/or monthly headache days [MHD]), and safety outcomes. The main outcome was the effectiveness measured by ≥50% response rate in MMD between the two groups. Secondary outcomes included other effectiveness measurements regarding the number of MMD and MHD and treatment emerging adverse events.

Results

A total of 388 patients with migraine under anti‐CGRP treatments (194 with autoimmune diseases and 194 age‐ and sex‐matched controls without autoimmune diseases) were included. The proportion of patients achieving a ≥50% response rate in MMD was higher in patients without autoimmune diseases at 6 (69% vs. 53%; p = 0.006) and 9 months (74% vs. 52%; p = 0.006). Treatment emerging adverse events were comparable between the two groups (35% vs. 38%; p = 0.575). Patients with autoimmune disease had a significantly lower likelihood of achieving a ≥50% response in MMD compared with those without autoimmune disease (adjusted odds ratio, 0.61; 95% confidence interval, 0.44–0.85; p = 0.006), independent of comorbid depression and medication overuse.

Conclusions

Our study shows that anti‐CGRP treatments are effective and safe for patients with migraine regardless the presence of autoimmune diseases, although an increased treatment response in patient without autoimmune disorders compared to patients with autoimmune disorders was observed. These findings highlight the need for early intervention, tailored strategies, and vigilant monitoring in patients with migraine and autoimmune disorders. Further research should explore immunomodulatory approaches to enhance outcomes. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAutoimmune DiseasesCalcitonin Gene-Related PeptideAntibodies, MonoclonalHumansFemaleMaleRetrospective StudiesAdultTreatment OutcomeMiddle Aged

Stichwörter der Autor:innen

anti‐CGRPautoimmunityimmunomodulatorymigraineneuroinflammationsafety

Substanzen

Calcitonin Gene-Related PeptideAntibodies, Monoclonal

Autor:innen und Institutionen

  • Facultad de Medicina, Universidad Autónoma de Madrid (UAM), Madrid, Spain.
  • Neurology and Immunology Department, Hospital Universitario de la Princesa, Madrid, Spain.
  • Headache Unit, Neurology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Health Research Institute of Valladolid (IBioVALL), Valladolid, Spain.
  • Headache Clinic, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

ORCID-Profile: María Clara García-Castillo, Álvaro Sierra-Mencía, Edoardo Caronna, Daniel Toledo-Alfocea, Alex Jaimes, Javier Casas-Limón, Albert Muñoz-Vendrell, Sonia Santos-Lasaosa, Marcos Polanco, Maria Dolores Villar-Martínez, Cristina Trevino-Peinado, Laura Rubio-Flores, Antonio Sánchez-Soblechero, Alberto Lozano-Ros, Ana Beatriz Gago-Veiga, Javier Díaz-De-Terán, Andrea Recio García, Sergio Campoy, Ane Mínguez-Olaondo, Vicente González-Quintanilla, Jesús Porta-Etessam, María-Luz Cuadrado, Ángel Luis Guerrero Peral, Patricia Pozo-Rosich, Jaime Rodríguez-Vico, Mariano Huerta-Villanueva, Julio Pascual, Peter J Goadsby, Alicia Gonzalez-Martinez

Förderung

  • Instituto de Salud Carlos III
  • European Union (FEDER/European Regional Development Fund-"A way to make Europe")

Zitieren

APA

García-Castillo, M. C., Sierra-Mencía, Á., Caronna, E., Toledo-Alfocea, D., Jaimes, A., Urtiaga, S., Casas-Limón, J., Muñoz-Vendrell, A., Santos-Lasaosa, S., García Martín, V., Martín Ávila, G., Polanco, M., Villar-Martínez, M. D., Trevino-Peinado, C., Rubio-Flores, L., Sánchez-Soblechero, A., Portocarrero Sánchez, L., Luque-Buzo, E., Lozano-Ros, A., …, & Gonzalez-Martinez, A. (2026). Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study. Headache: The Journal of Head and Face Pain, 66(6), 1330-1341. https://doi.org/10.1111/head.70086

Vancouver

García-Castillo MC, Sierra-Mencía Á, Caronna E, Toledo-Alfocea D, Jaimes A, Urtiaga S, et al. Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study. Headache: The Journal of Head and Face Pain. 2026;66(6):1330-1341. doi:10.1111/head.70086

BibTeX
@article{GarcaCastillo2026,
  author = {García-Castillo, María Clara and Sierra-Mencía, Álvaro and Caronna, Edoardo and Toledo-Alfocea, Daniel and Jaimes, Alex and Urtiaga, Sarai and Casas-Limón, Javier and Muñoz-Vendrell, Albert and Santos-Lasaosa, Sonia and García Martín, Valvanuz and Martín Ávila, Guillermo and Polanco, Marcos and Villar-Martínez, Maria Dolores and Trevino-Peinado, Cristina and Rubio-Flores, Laura and Sánchez-Soblechero, Antonio and Portocarrero Sánchez, Leonardo and Luque-Buzo, Elisa and Lozano-Ros, Alberto and Gago-Veiga, Ana Beatriz and Díaz-De-Terán, Javier and Recio García, Andrea and Canales Rodríguez, Javiera and Gómez García, Andrea and González Salaices, Marta and Campoy, Sergio and Mínguez-Olaondo, Ane and Maniataki, Stefania and González-Quintanilla, Vicente and Porta-Etessam, Jesús and Cuadrado, María-Luz and Guerrero Peral, Ángel Luis and Pozo-Rosich, Patricia and Rodríguez-Vico, Jaime and Huerta-Villanueva, Mariano and Pascual, Julio and Goadsby, Peter J and Gonzalez-Martinez, Alicia},
  title = {Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {6},
  pages = {1330--1341},
  doi = {10.1111/head.70086}
}
Kostenlos starten →